

Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Yasuo Suzuki¹ · Satoshi Motoya² · Hiroyuki Hanai³ · Toshifumi Hibi⁴ ·
Shiro Nakamura⁵ · Andreas Lazar⁶ · Anne Martin Robinson⁷ · Martha Skup⁷ ·
Nael Mohamed Mostafa⁷ · Bidan Huang⁷ · Roopal Thakkar⁷ · Mamoru Watanabe⁸

Published online: 12 April 2017
© Japanese Society of Gastroenterology 2017

Erratum to: J Gastroenterol DOI 10.1007/s00535-017-1325-2

The authors would like to correct the error in the publication of the original article. The corrected detail is published with this erratum for your reading.

Acknowledgements The study was designed, conducted, and funded by AbbVie Inc and Eisai Co, Ltd. AbbVie Inc participated in the interpretation of data, review, and approval of the manuscript. Vicki Schwartz and Alessia Piazza provided medical writing and editorial support in the preparation of this manuscript, which was funded by AbbVie Inc.

The online version of the original article can be found under doi:[10.1007/s00535-017-1325-2](https://doi.org/10.1007/s00535-017-1325-2).

✉ Toshifumi Hibi
thibi@insti.kitasato-u.ac.jp

- ¹ Toho University Medical Center Sakura Hospital, Chiba, Japan
- ² IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan
- ³ Hamamatsu South Hospital, Shizuoka, Japan
- ⁴ IBD Centre, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan
- ⁵ Hyogo College of Medicine Hospital, Nishinomiya, Hyogo, Japan
- ⁶ AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
- ⁷ AbbVie, Inc., North Chicago, IL, USA
- ⁸ Department of Gastroenterology, Tokyo Medical and Dental University, Tokyo, Japan